Researchers at Charité – Universitätsmedizin Berlin have developed crossNN, an artificial intelligence model that can classify more than 170 cancer types using DNA methylation patterns. The system achieves 99.1% precision for brain tumours and 97.8% for pan-cancer classification, working across multiple sequencing platforms including nanopore technology.
A new pressure-driven method for generating individual droplets at microfluidic T-junctions offers precise temporal control over droplet formation. The technique, validated through theoretical modelling and experimental testing, promises to advance lab-on-a-chip technologies for chemical analysis, diagnostics, and biological research applications.
German biotechnology firm TQ Therapeutics GmbH has strategically acquired Juno Therapeutics GmbH, dramatically expanding capabilities for developing next-generation ultra-short extracorporeal cell and gene therapy systems that could transform patient access to personalised cellular treatments.
Tagomics Ltd has secured £860,000 in Innovate UK Biomedical Catalyst funding to develop a sophisticated diagnostic test for early colorectal cancer detection, forming part of a £1.2 million project that could transform cancer screening capabilities. The Cambridge-based biomarker discovery company will customise its proprietary Interlace platform to identify genetic and epigenetic mutations associated with colorectal […]
Roche has announced a strategic collaboration with Broad Clinical Labs to develop clinical applications for its Sequencing by Expansion (SBX) technology, with an initial focus on whole genome sequencing for critically ill newborns and their biological parents. The partnership aims to establish genomic sequencing as routine clinical practice in neonatal intensive care units.
SpliceBio has secured US$135 million in Series B funding to tackle one of gene therapy’s most persistent technical barriers: the packaging capacity limitations that have rendered many genetic diseases untreatable. The Barcelona-based company’s breakthrough protein splicing technology promises to unlock therapeutic potential for conditions caused by genes too large for conventional delivery systems.
French clinical-stage biotechnology company Enterome SA has raised US$19 million in private financing to advance its lead OncoMimics™ immunotherapy candidate EO2463 for treating indolent non-Hodgkin lymphoma, with particular focus on patients in the “watch-and-wait” category who currently lack approved treatment options.
German biotech company osteolabs GmbH has secured a pivotal distribution partnership with leading Swiss medical laboratory ‘labor team’, bringing cutting-edge calcium isotope technology to Switzerland and Liechtenstein’s healthcare systems and with the aim of transforming bone health diagnostics for over half a million patients.
Biotechnology giant Biogen has entered into a strategic research partnership with privately held City Therapeutics to develop novel RNA interference-based therapeutics for central nervous system diseases, combining next-generation RNAi engineering with proprietary drug delivery technologies.
F. Hoffmann-La Roche has announced an ambitious US$50 billion investment initiative spanning five years, designed to transform the company’s United States pharmaceutical and diagnostics infrastructure. The comprehensive expansion programme addresses critical manufacturing bottlenecks whilst establishing cutting-edge research capabilities across multiple therapeutic domains, creating over 12,000 new positions in the biomedical technology sector.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.